Nicotine vaccines

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 8, 2011, Pages 905-915

  Fahim, Raafat E F ^a   Kessler, Paul D ^a   Fuller, Steven A ^a   Kalnik, Matthew W ^a  

^a Nabi Biopharmaceuticals   (United States)

Author keywords

Adjuvant; Bupropion; Combination therapy; Nicotine vaccine; Smoking cessation; Varenicline

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BACTERIAL TOXIN; CEVARIX; CHOLERA TOXIN B SUBUNIT; DOPAMINE; ENERGIX; HAPTEN; HEPATITIS B VACCINE; NIC 002; NICCINE; NICOTINE; NICOTINE DERIVATIVE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC AGENT; NORADRENALIN; NORTRIPTYLINE; RECOMBINANT DNA; SEROTONIN UPTAKE INHIBITOR; TA NIC VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VARENICLINE; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ANTIBODY TITER; ARTICLE; BEHAVIOR MODIFICATION; BRAIN; CENTRAL NERVOUS SYSTEM; CIGARETTE SMOKING; CLINICAL TRIAL (TOPIC); CONJUGATE VACCINE TECHNOLOGY; CROSS REACTION; DRUG DESIGN; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MEDICAL TECHNOLOGY; MORTALITY; NEUROTOXICITY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PATIENT COUNSELING; PERSONALIZED MEDICINE; RELAPSE; SMOKING CESSATION; SYMPTOM; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84857722713     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711799219343     Document Type: Article

References (85)

1. World Health Organization Fact Sheet http,//www.who.int/mediacentre/factsheets/fs339/en/index.htm [Accessed, October 28, 2011].
2. Davis, R.M., Wakefield, M., Amos, A., Gupta, P.C. The Hitchhiker's Guide to Tobacco Control, a global assessment of harms, remedies, and controversies. Annu. Rev. Public Health, 2007, 28, 171-194.
3. Centers for Disease Control and Prevention. Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses--- United States, 2000-2004. MMWR, 2008, 57, 1226-8.
4. McGinnis, J.M.; Foege, W.H. Actual causes of death in the United States. JAMA, 1993, 270, 2207-2211.
5. Fiore, M.C.; Jaen, C.R.; Baker, T.B.; Bailey, W.C.; Benowitz, N.L.; Curry, S.J.; Dorfman, S.F.; Froelicher, E.S.; Goldstein, M.G.; Healton, C.G.; Henderson, P.N.; Heyman, R.B.; Koh, H.K.; Kottke, T.E.; Lando, H.A.; Mecklenburg, R.E.; Mermelstein, R.J.; Mullen, P.D.; Orleans, C.T.; Robinson, L.; Stitzer, M.L.; Tommasello, A.C.; Villejo, L.; Wewers, M.E. Treating Tobacco Use and Dependence, 2008 Update. Clinical Practice Guideline. Rockville, MD, US Department of Health and Human Services, Public Health Service, May 2008.
6. Fiore, M.C.; Bailey, W.C.; Cohen, S.J.; Dorfman, S.F.; Goldstein, M.G.; Gritz, E.R.; Heyman, R.B.; Jaén, C.R.; Kottke, T.E.; Lando, H.A.; Mecklenburg, R.E.; Mullen, P.D.; Nett, L.M.; Robinson, L.; Stitzer, M.L.; Tommasello, A.C.; Villejo, L.; Wewers, M.E. Treating Tobacco Use and Dependence, Clinical Practice Guideline June 2000. U.S. Department of Health and Human Services, Agency for Research and Quality, Rockville, MD, June 2000.
7. Jasinski, D.R.; Henningfeld, J.E. Pharmacologic basis for nicotine replacement. Prog. Clin. Biol. Res., 1988, 261, 35-61.
8. Eisenberg, M.J.; Filion, K.B.; Yavin, D.; Bélisle, P.; Mottillo, S.; Joseph, L.; Gervais, A.; O'Loughlin, J.; Paradis, G.; Rinfret, S.; Pilote, L. Pharmacotherapies for smoking cessation, a metaanalysis of randomized controlled trials. Can. Med. Assoc. J., 2008, 179, 135-144.
9. Hughes, J.R.; Stead, L.F.; Lancaster, T. Antidepressants for Smoking Cessation. Cochrane Database Syst Rev., 2007, 24(1), CD000031.
10. Jorenby, D.E.; Hays, J.T.; Rigotti, N.A.; Azoulay, S.; Watsky, E.J.; Williams, K.E.; Billing, C.B.; Gong, J.; Reeves, K.R.; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation, a randomized controlled trial. JAMA, 2006, 296, 56-63.
11. Gonzales, D.; Rennard, S.I.; Nides, M.; Oncken, C.; Azoulay, S.; Billing, C.B.; Watsky, E.J.; Gong, J.; Williams, K.E.; Reeves, K.R. Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation. JAMA, 2006, 296, 1, 47-55.
12. Hatsukami, D.K.; Mooney, M.E. Pharmacological and behavioral strategies for smoking cessation. J. Clin. Psychol. Med. Sett., 1999, 6, 11-38.
13. Colburn, W.A. Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic/toxicologic effects of drugs. Drug Metab. Rev., 1980, 11, 223-262.
14. Scherrmann, J.M.; Terrien, N.; Urtizberea, M.; Pierson, P.; Denis, H.; Bourre, J.M. Immunotoxicotherapy: present status and future trends. J. Clin. Toxicol., 1989, 27, 1-35.
15. Ochs, H.R.; Smith, T.W. Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. J. Clin. Invest., 1977, 60, 1303-1313.
16. Brunn, G.J.; Keyler, D.E.; Pond, S.M.; Pentel, P.R. Reversal of desipramine toxicity in rats using drug-specific antibody Fab fragments, Effects on hypotension and interaction with sodium bicarbonate. J. Pharmacol. Exp. Ther., 1992, 260, 1392-1399.
17. Owens, S.M.; Mayersohn, M. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab. Dispos., 1986, 14, 52-58.
18. Baud, F.J.; Sabouraud, A.; Vicaut, E.; Taboulet, P.; Lang, J.; Bismuth, C.; Rouzioux, J.M.; Scherrmann, J.M. Brief report: Treatment of severe colchicine overdose with colchicine-specific Fab fragments. N. Engl. J. Med., 1995, 332, 642-645.
19. Bonese, K.F.; Wainer, B.H.; Fitch, F.W.; Rothberg, R.M.; Schuster, C.R. Changes in heroin self-administration by rhesus monkey after morphine immunization. Nature, 1974, 252, 708-710.
20. Fox, B.S.; Kantak, K.M.; Edwards, M.A.; Black, K.M.; Bollinger, B.K.; Botka, A.J.; French, T.L.; Thompson, T.L.; Schad, V.C.; Greenstein, J.L.; Gefter, M.L.; Exley, M.A.; Swain, P.A.; Briner, T.J. Efficacy of therapeutic cocaine vaccine in rodent models. Nat. Med., 1996, 2, 1129-1132.
21. Gunnell, D.; Irvine, D.; Wise, L.; Davies, C.; Martin, R.M. Varenicline and suicidal behaviour, a cohort study based on data from the General Practice Research Database. BMJ, 2009, 339, b3805.
22. Turcotte, S.; Rosenberg, S.A. Immunotherapy for metastatic solid cancers. Adv. Surg., 2011, 45, 341-360.
23. Fay, K.E.; Lai, J.; Bocchini, J.A., Jr. Update on childhood and adolescent immunizations, selected review of US recommendations and literature, part 1. Curr. Opin. Pediatr., 2011, 23, 460-469.
24. St. Clair, R.J.; Akers, C.C.R.; Vanhinsbergh, L.; McKenna, K.A.; Wood, D.M.; Jack, L. Longitudinal Safety And Immunogenicity Data Of TA-NIC, A Novel Nicotine Vaccine. Ninth Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA, February 19-22, 2003.
25. Crucell. Products-Dukerol. http://www.crucell.com/Products/Dukoral (accessed December 29, 2011)
26. Qadri, F.; Ahmed, T.; Ahmed, F.; Bradley, Sack, R.; Sack, D.A.; Svennerholm, A.M. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine, 2003, 21, 2394-2403.
27. St Clair, R.J.; Dobson, J.; Wood, D.; Settles, M. Safety and immunogenicity of a human nicotine conjugate vaccine. Drug Alcohol Depend., 2002, 66, s148.
28. News Release. Xenova Group plc. Successful Results from Second Clinical Trial of Anti-Smoking Vaccine, TA-NIC. Slough, UK, 14 July 2004. http://investegate.info/Article.aspx?id=200407140743398196A (accessed December 29, 2011)
29. News Release. Xenova Group plc. Anti-Smoking Vaccine TA-NIC Preliminary 12 Month Clinical Trial Results. Slough, UK, 3 March 2005. http://hugin.info/133161/R/982993/146255.pdf (accessed December 29, 2011)
30. Long, M. Quest for vaccines to treat addiction. Wall Street J., 2011, D1.
31. de Villiers, S.H. Active Immunization against Nicotine Dependence. PhD Thesis, Department of Physiology and Phamacology: Karolinska Institute, Stockholm, Sweden, 2010.
32. Lindblom, N.; de Villiers, S.H.; Kalayanov, G.; Gordon, S.; Johansson, A.M.; Svensson, T.H. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration, 2002, 69, 254-260.
33. de Villiers, S.H.; Lindblom, N.; Kalayanov, G.; Gordon, S.; Malmerfelt, A.; Johansson, A.M.; Svensson, T.H. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration, 2002, 69, 247-253.
34. de Villiers, S.H.; Lindblom, N.; Kalayanov, G.; Gordonb, S.; Baraznenok, I.; Malmerfelt, A.; Marcus, M.M.; Johansson, A.M.; Svensson, T.H. Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine, 2010, 28, 2161-2168.
35. Degling-Wikingsson, L. Relapse Prevention and Long-term Abstinence with Niccine. Examining strategies for development and implementing new and existing smoking cessation therapies. In: 2nd Annual Visiongain Smoking Cessation Conference, London, United Kingdom, January 26-27, 2009.
36. Maurer, P.; Jennings, G.T.; Willers, J.; Rohner, F.; Lindman, Y.; Roubicek, K.; Renner, W.A.; Muller, P.; Bachmann, M.F. A therapeutic vaccine for nicotine dependence, preclinical efficacy, and phase I safety and immunogenicity. Eur. J. Immunol., 2005, 35, 2031-2040.
37. Cornuz, J.; Klingler, K.; Müller, P.; Jungi, W.F.; Cerny, T. A therapeutic vaccine for nicotine dependence, Results of a phase I and a randomized phase II study. J. Clin. Oncol., 2005, 23(16S), 1008.
38. Cornuz, J.; Zwahlen, S.; Jungi, W.F.; Osterwalder, J.; Klingler, K.; van Melle, G.; Bangala, Y.; Guessous, I.; Müller, P.; Willers, J.; Maurer, P.; Bachmann, M.F.; Cerny, T. A vaccine against nicotine for smoking cessation, a randomized controlled trial. PLoS One, 2008, 3, e2547.
39. Hatsukami, D.K.; Jorenby, D.E.; Gonzales, D.; Rigotti, N.A.; Glover, E.D.; Oncken, C.A.; Tashkin, D.P.; Reus, V.I.; Akhavain, R.C.; Fahim, R.E.; Kessler, P.D.; Niknian, M.; Kalnik, M.W.; Rennard, S.I. Clin. Pharmacol. Ther., 2011, 89, 392-399.
40. Cytos Biotechnology, Company Press Release, October 15, 2009.
41. Fattom, A.I.; Horwith, G.; Fuller, S.; Propst, M.; Naso, R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection, from the lab bench to phase III clinical trials, 2004, 22, 880-887.
42. Lin, F.Y.; Ho, V.A.; Khiem, H.B.; Trach, D.D.; Bay, P.V.; Thanh, T.C.; Kossaczka, Z.; Bryla, D.A.; Shiloach, J.; Robbins, J.B.; Schneerson, R.; Szu, S.C. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med., 2001, 344, 1263-1269.
43. Pentel, P.R.; Malin, D.H.; Ennifar, S.; Hieda, Y.; Keyler, D.E.; Lake, J.R.; Milstein, J.R.; Basham, L.E.; Coy, R.T.; Moon, J.W.D.; Naso, R.; Fattom, A. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav., 2000, 65, 191-198.
44. Hieda, Y.; Keyler, D.E.; Ennifar, S.; Fattom, A.; Pentel, P.R. Vaccination against nicotine during continued nicotine administration in rats, immunogenicity of the vaccine and effects on nicotine distribution to brain. Int. J. Immunopharmacol., 2000, 22, 809-819.
45. Hieda, Y.; Keyler, D.E.; VandeVoort, J.T.; Kane, J.K.; Ross, C.A.; Raphael, D.E.; Niedbalas, R.S.; Pentel, P.R. Active immunization alters the plasma nicotine concentration in rats. J. Pharmacol. Exp. Ther., 1997, 283, 1076-1081.
46. Hieda, Y.; Keyler, D.; VandeVoort, J.; Niedbalas, R.; Raphael, D.; Ross, C.; Pentel, P.R. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology, 1999, 143, 150-157.
47. Pentel, P.R.; Dufek, M.B.; Roiko, S.A.; LeSage, M.G.; Keyler, D.E. Differential effects of passive immunization with nicotinespecific antibodies on the acute and chronic distribution of nicotine to brain in rats. J. Pharmacol. Exp. Ther., 2006, 317, 660-666.
48. Malin, D.H.; Lake, J.R.; Lin, A.; Saldona, M.; Bolch, L.; Lorado Irvin, M.L.; Chandrasekora, H.; Alvarado, C.L.; Hieda, Y.; Keyler, D.E.; Pentel, P.R.; Ennifar, S.; Basham, L.E.; Naso, R.; Fattom, A. Passive Immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol. Biochem. Behav., 2001, 68, 87-92.
49. Hatsukami, D.K.; Rennard, S.; Jorenby, D.; Fiore, M.; Koopmeiners, J.; de Vos, A.; Horwith, G.; Pentel, P.R. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther., 2005, 78, 456-467.
50. Wagena, E.J.; de Vos, A.; Horwith, G.; van Schayck, C.P. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers, results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob. Res., 2008, 10(1), 213-218.
51. Nabi Biopharmaceuticals data on file.
52. Zhou, X.; Nonnemaker, J.; Sherrill, B.; Gilsenan, A.W.; Coste, F.; West, R. Attempts to quit smoking and relapse, factors associated with success or failure from the ATTEMPT cohort study. Addict. Behav., 2009, 34, 365-373.
53. Hughes, J.R.; Callas, P.W. Is Delaying a Quit Attempt Associated With Less Success? Nicotine Tob. Res., 2011, 13(12), 1228-1232.
54. Brunner, R.; Jensen-Jarolim, E.; Pali-Schöll, I. The ABC of clinical and experimental adjuvants--a brief overview. Immunol. Lett., 2010, 128, 29-35.
55. Keyler, D.E.; Roiko, S.A.; Earley, C.A.; Murtaugh, M.P.; Pentel, P.R. Enhanced immunogenicity of a bivalent nicotine vaccine. Int. Immunopharmacol., 2008, 8, 1589-1594.
56. Garçon, N.; Segal, L.; Tavares, F.; Van Mechelen, M. The safety evaluation of adjuvants during vaccine development, the AS04 experience. Vaccine, 2011, 29, 4453-4459.
57. Paavonen, J.; Naud, P.; Salmerón, J.; Wheeler, C.M.; Chow, S.N.; Apter, D.; Kitchener, H.; Castellsague, X.; Teixeira, J.C.; Skinner, S.R.; Hedrick, J.; Jaisamrarn, U.; Limson, G.; Garland, S.; Szarewski, A.; Romanowski, B.; Aoki, F.Y.; Schwarz, T.F.; Poppe, W.A.; Bosch, F.X.; Jenkins, D.; Hardt, K.; Zahaf, T.; Descamps, D.; Struyf, F.; Lehtinen, M.; Dubin, G. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA), final analysis of a double-blind, randomised study in young women. Lancet, 2009, 374, 301-314.
58. Cooper, C.; Mackie, D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine, a review of HEPLISAV™ safety and efficacy. Expert Rev. Vaccines, 2011, 10, 417-427.
59. Murad, Y.M.; Clay, T.M.; Lyerly, H.K.; Morse, M.A. CPG-7909 (PF-3512676, ProMune), toll-like receptor-9 agonist in cancer therapy. Expert Opin. Biol. Ther., 2007, 7, 1257-1266.
60. Cooper, C.L.; Angel, J.B.; Seguin, I.; Davis, H.L.; Cameron, D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIVinfected adults achieves long-term seroprotection for up to 5 years. Clin. Infect. Dis., 2008, 46, 1310-1314.
61. Cooper, C.L.; Davis, H.L.; Morris, M.L.; Efler, S.M.; Adhami, M.A.; Krieg, A.M.; Cameron, D.W.; Heathcote, J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults, a doubleblind phase I/II study. J. Clin. Immunol., 2004, 24, 693-701.
62. Chen, X.; Kim, P.; Farinelli, B.; Doukas, A.; Yun, S.H.; Gelfand, J.A.; Anderson, R.R.; Wu, M.X. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS One, 2010, 5, e13776.
63. Gu, F.; Zhang, L.; Teply, B.A.; Mann, N.; Wang, A.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. USA, 2008, 105, 2586-2591.
64. Hicks, M.J.; De BP, Rosenberg JB, Davidson JT, Moreno AY, Janda KD, Wee S, Koob GF, Hackett NR, Kaminsky SM, Worgall S, Toth M, Mezey JG, Crystal RG. Cocaine analog coupled to disrupted adenovirus, a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol. Ther., 2011, 19, 612-619.
65. Harvey, B.G.; Hackett, N.R.; El-Sawy, T.; Rosengart, T.K.; Hirschowitz, E.A.; Lieberman, M.D.; Lesser, M.L.; Crystal, R.G. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol., 1999, 73, 6729-6742.
66. Harvey, B.G.; Maroni, J.; O'Donoghue, K.A.; Chu, K.W.; Muscat, J.C.; Pippo, A.L.; Wright, C.E.; Hollmann, C.; Wisnivesky, J.P.; Kessler, P.D.; Rasmussen, H.S.; Rosengart, T.K.; Crystal, R.G. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther., 2002, 13, 15-63.
67. Kornitzer, M.; Boutsen, M.; Dramaix, M.; Thijs, J.; Gustavsson, G. Combined use of nicotine patch and gum in smoking cessation, a placebo-controlled trial. Prev. Med., 1995, 24, 41-47.
68. Blöndal, T.; Franzon, M.; Westein, A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur. Respir J., 1997, 10, 1585-1590.
69. Steinberg, M.B.; Greenhaus, S.; Schmelzer, A.C.; Bover, M.T.; Foulds, J.; Hoover, D.R.; Carson, J.L. Triple-combination pharmacotherapy for medically ill smokers, a randomized trial. Ann. Intern. Med., 2009, 150, 447-454.
70. Ebbert, J.O.; Burke, V.M.; Hays, J.T.; Hurt, R.D. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob. Res., 2009, 11, 572-576.
71. Ebbert, J.O.; Croghan, I.T.; Sood, A.; Schroeder, D.R.; Hays, J.T.; Hurt, R.D. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob. Res., 2009, 11, 234-239.
72. Wheeler, C.J.; Das, A.; Liu, G.; Yu, J.S.; Black, K.L. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res., 2004, 10, 5316-5326.
73. Arlen, P.M.; Gulley, J.L.; Parker, C.; Skarupa, L.; Pazdur, M.; Panicali, D.; Bettham, P.; Tsang, K.Y.; Grosenbach, D.W.; Feldman, J.; Steinberg, S.M.; Jones, E.; Chen, C.; MArte, J.; Schlom, J.; Dahut, W. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res., 2006, 12, 1260-1269.
74. Antonia, S.J.; Mirza, N.; Fricke, I.; Chiapporil, A.; Thompson, P.; Williams, N.; Bepler, G.; Simon, G.; Janssen, W.; Lee, J.-H.; Menander, K.; Chada, S.; Gabrilovich, D.I. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res., 2006, 12, 878-887.
75. Gribben, J.G.; Ryan, D.P.; Boyajian, R.; Urban, R.G.; Hedley, M.L.; Beach, K.; Nealon, P.; Matulonis, U.; Campos, S.; Gilligan, T.D.; Richardson, P.G.; Marshall, B.; Neuberg, D.; Nadler, L.M. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin. Cancer Res., 2005, 11, 4430-4436.
76. Tonstad, S.; Tønnesen, P.; Hajek, P.; Williams, K.E.; Billing, C.B.; Reeves, K.R. Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation, a randomized controlled trial. JAMA, 2006, 296, 64-71.
77. Roiko, S.A.; Harris, A.C.; Keyler, D.E.; Lesage, M.G.; Zhang, Y.; Pentel, P.R. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J. Pharmacol. Exp. Ther., 2008, 325, 985-993.
78. Vink, J.M.; Willemsen, G.; Boomsma, D.I. Heritability of smoking initiation and nicotine dependence. Behav. Genet., 2005, 35, 397-406.
79. Improgo, M.R.; Scofield, M.D.; Tapper, A.R.; Gardner, P.D. The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster, dual role in nicotine addiction and lung cancer. Prog. Neurobiol., 2010, 92, 212-226.
80. Hukkanen, J.; Jacob, P., 3rd.; Benowitz, N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev., 2005, 57, 79-115.
81. Dempsey, D.; Tutka, P.; Jacob, P., 3rd.; Allen, F.; Schoedel, K.; Tyndale, R.F.; Benowitz, N.L. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther., 2004, 76, 64-72.
82. Schnoll, R.A.; Patterson, F.; Wileyto, E.P.; Tyndale, R.F.; Benowitz, N.; Lerman, C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine, a validation study. Pharmacol. Biochem. Behav., 2009, 92, 6-11.
83. Lerman, C.; Tyndale, R.; Patterson, F.; Wileyto, E.P.; Shields, P.G.; Pinto, A.; Benowitz, N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther., 2006, 79, 600-608.
84. Patterson, F.; Schnoll, R.A.; Wileyto, E.P.; Pinto, A.; Epstein, L.H.; Shields, P.G.; Hawk, L.W.; Tyndale, R.F.; Benowitz, N.; Lerman, C. Toward personalized therapy for smoking cessation, a randomized placebo-controlled trial of bupropion. Clin. Pharmacol. Ther., 2008, 84, 320-325.
85. Pharmacogenomics Research Network (PGRN). Pharmacogenetics of Nicotine Addiction Treatment http://pgrn.org/display/pgrnwebsite/PNAT+Profile (accessed December 29, 2011).